Comment from Endocrine Technology, LLC

Summary: Endocrine Technology, LLC, a biotechnology company, supports the pilot program by highlighting how their AI-enabled technology and nano-formulated drug (NSPS) can optimize clinical trials and address public health emergencies. They argue that their technology can expedite the development of life-saving therapeutics for hemorrhagic viruses and other pathogens by overcoming existing limitations in immunology and genomics.